Article Information
History
- March 9, 2020.
Article Versions
- Version 1 (March 6, 2020 - 04:47).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Federica Cappuccini1,
- Richard Bryant2,3,
- Emily Pollock1,
- Lucy Carter1,
- Clare Verrill2,4,
- Julianne Hollidge2,3,
- Ian Poulton1,
- Megan Baker1,
- Celia Mitton1,
- Andrea Baines1,
- Armin Meier5,
- Guenter Schmidt5,
- Richard Harrop6,
- Andrew Protheroe7,
- Ruth MacPherson8,
- Steven Kennish9,
- Susan Morgan10,
- Selena Vigano11,
- Pedro Romero11,
- Thomas Evans12,
- James W.F. Catto13,
- Freddie Hamdy2,3,
- Adrian V.S. Hill1,* and
- Irina Redchenko1,*,#
- 1The Jenner Institute, University of Oxford, Oxford, UK
- 2Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- 3Department of Urology, Churchill Hospital Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 4Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
- 5Definiens GmbH, Munich, Germany
- 6Oxford Biomedica UK limited, Oxford, UK
- 7Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 8Department of Radiology, Churchill Hospital Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 9Department of Radiology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
- 10Department of Pathology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
- 11Lausanne University Hospital, Lausanne, Switzerland
- 12Vaccitech UK limited, Oxford, UK
- 13Academic Urology Unit, University of Sheffield, Sheffield, UK
- ↵#To whom correspondence should be addressed: irina.redchenko{at}ndm.ox.ac.uk
↵* These authors contributed equally to this work
Posted March 09, 2020.
Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial
